clinical trial

Nutrition

Long-Term Sardine Consumption and Gender-Equalized Longevity: 10-Year Results from a Portuguese Cohort Study

Summary of Key Findings This paper reports on a 20-year study examining whether regular sardine consumption affects longevity and reduces gender gaps in life expectancy. The study tracked 400 participants (200 Portuguese and 200 Portuguese-Canadians) who consumed sardines every other day for 10 years. Study Design and Participants Key Results After 10 Years Theoretical Background […]

, , , , , , , , , ,

Long-Term Sardine Consumption and Gender-Equalized Longevity: 10-Year Results from a Portuguese Cohort Study Read Post »

Research

Herpes Zoster Vaccine Reduces Dementia Risk by 20% in Welsh Natural Experiment

Study Design & Methodology Researchers used a unique natural experiment in Wales to study the causal effect of live-attenuated herpes zoster vaccination (Zostavax) on dementia. They exploited a sharp eligibility cutoff where: This created an abrupt change in vaccination rates (from 0.01% to 47.2%) between nearly identical populations, allowing researchers to bypass traditional confounding concerns

, , , , , , , , , ,

Herpes Zoster Vaccine Reduces Dementia Risk by 20% in Welsh Natural Experiment Read Post »

Research

Spermidine Intake Reduces Mortality Risk by 24% in 20-Year Human Study: Dietary Polyamine Shows Anti-Aging Effects Equivalent to Being 5.7 Years Younger

Main Findings This prospective study provides the first evidence that higher dietary spermidine intake significantly reduces all-cause mortality in humans. The research demonstrates a strong dose-response relationship, with participants in the highest tertile of spermidine consumption showing mortality risks equivalent to being 5.7 years younger. Study Design and Population Primary Cohort: Bruneck Study Validation Cohort:

, , , , , , , , , , , , , , ,

Spermidine Intake Reduces Mortality Risk by 24% in 20-Year Human Study: Dietary Polyamine Shows Anti-Aging Effects Equivalent to Being 5.7 Years Younger Read Post »

Research

7-Year Clinical Trial Shows Synergistic Effects of Combined Telmisartan-Rosuvastatin Therapy in Preventing Dementia Among Elderly Hypertensive Patients, with Enhanced Benefits for APOE ε4 Carriers

TL;DR: A 7-year randomized clinical trial found that combining telmisartan (blood pressure medication) and rosuvastatin (cholesterol medication) significantly reduced dementia risk and cognitive decline in elderly hypertensive patients. The combination was particularly effective for patients carrying the APOE ε4 gene variant, which is associated with increased dementia risk. Key Findings: This study provides strong evidence

, , , , , , , , , , , , , ,

7-Year Clinical Trial Shows Synergistic Effects of Combined Telmisartan-Rosuvastatin Therapy in Preventing Dementia Among Elderly Hypertensive Patients, with Enhanced Benefits for APOE ε4 Carriers Read Post »

Scroll to Top